- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03699436
Effectiveness of Electric Stimulation Therapy in Raynaud's Phenomenon
Effectiveness of an Intervention Program With Electric Stimulation Therapy in Patients With Raynaud's Phenomenon: a Randomized Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Raynaud's Phenomenon is a disorder that causes pain and functional limitation in people who suffer it.
Investigators considerer that the application of an electrotherapy intervention with galvanic current, thanks to its vasodilator action, will produce clinically significant improvements in the number of attacks, temperature and blood flow of patients with Raynaud's Phenomenon, which can lead to a decrease in pain associated, frequency and severity of ischemic attacks and therefore an improvement in the functionality of the upper limbs.
The experimental group will receive an electrotherapy treatment using galvanic current. To apply the treatment, we will place the patient seated, with their hands inside two containers filled with water up to the limit of their nails without touching them. Next we will connect the electrodes and apply a galvanic current for 10 minutes, there will be a minute of rest for the patient while we change the polarity of this current and we will apply it another 10 minutes. The intensity of the current depends on the threshold of the patient.
The control group will maintain their usual conservative and pharmacological treatment without receiving electrotherapy
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Granada, Spain, 18001
- University of Granada
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Being over 18 years of age.
- Being diagnosed with Primary or Secondary Raynaud Phenomenon according to the criteria established by LeRoy-Medsger.
- A history of at least one year of regular attacks of pallor or acral cyanosis caused by exposure to cold and/or stress.
- Having signed the informed consent document and willingness to participate in the study
Exclusion Criteria:
- Presence of skin alterations such as stings, scars, ulcers or gangrene in the examined area.
- Suffering upper limb entrapment syndrome, central nervous system polyneuropathy, Hypothyroidism, renal failure, cerebral or cardiac ischemic disease.
- History of drug or alcohol abuse.
- Pregnant or breastfeeding women.
- Use of vibratory tools.
- Participants with tumour process.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Electric Stimulation Therapy Group
The experimental group will receive an electrotherapy treatment with galvanic current in their hands.
Electrotherapy with galvanic current has vasodilator action.
|
The experimental group will receive an electrotherapy treatment with galvanic current in their hands.This protocol will be administered at weekly sessions of 30 minutes with a period of 3 times / week with a total of 20 sessions, distributed over a 7-week period.
They will be evaluated at baseline, after the end of the last treatment session and after two months of follow-up.
Other Names:
|
Active Comparator: Control Group
The control group will be subjected to a conservative treatment.
These patients will continue to take their usual medication and will not receive electrotherapy treatment
|
The control group continue with their usual conservative and pharmacological treatment and will not receive electrotherapy treatment.
They will be evaluated too at baseline, after the end of the last treatment session and after two months of follow-up.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Raynaud´s Phenomenon attacks
Time Frame: Seven Weeks
|
Change from baseline at the Number of Raynaud´s Phenomenon attacks
|
Seven Weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Temperature in the affected areas in patients with Raynaud´s Disease
Time Frame: Seven weeks
|
Change from baseline temperature in the infrared thermography in patients with Raynaud´s Disease
|
Seven weeks
|
Temperature in the affected areas in patients with Raynaud´s Disease
Time Frame: Fifteen weeks
|
Change from baseline temperature in the infrared thermography in patients with Raynaud´s Disease
|
Fifteen weeks
|
Temperature in the Cold Stress Test
Time Frame: Seven weeks
|
Change from temperature in the Cold Stress Test
|
Seven weeks
|
Temperature in the Cold Stress Test
Time Frame: Fifteen weeks
|
Change from temperature in the Cold Stress Test
|
Fifteen weeks
|
Pain Intensity: Visual Analog Scale
Time Frame: Seven weeks
|
Change from baseline in pain in the Visual Analog Scale.
Score range between 0-10 cm where 0 is in considerer no pain and 10 is the worst pain imaginable.
|
Seven weeks
|
Pain Intensity: Visual Analog Scale
Time Frame: Fifteen weeks
|
Change from baseline in pain in the Visual Analog Scale.
Score range between 0-10 cm where 0 is in considerer no pain and 10 is the worst pain imaginable.
|
Fifteen weeks
|
Central Sensitization
Time Frame: Seven weeks
|
Change from baseline in the Central Sensitization Inventory.
The cumulative score ranges from 0 to 100.Higher scores indicate increased frequency and severity of the symptoms.
|
Seven weeks
|
Central Sensitization
Time Frame: Fifteen weeks
|
Change from baseline in the Central Sensitization Inventory.
The cumulative score ranges from 0 to 100.Higher scores indicate increased frequency and severity of the symptoms.
|
Fifteen weeks
|
Pain Catastrophizing
Time Frame: Seven weeks
|
Change from baseline in the Pain Catastrophizing Scale.
Score range is from 0 to 52; higher scores indicate a greater frequency of catastrophic thoughts.
|
Seven weeks
|
Pain Catastrophizing
Time Frame: Fifteen weeks
|
Change from baseline in the Pain Catastrophizing Scale.
Score range is from 0 to 52; higher scores indicate a greater frequency of catastrophic thoughts.
|
Fifteen weeks
|
Oxygen Saturation
Time Frame: Seven weeks
|
Change from baseline in Oxygen Saturation
|
Seven weeks
|
Oxygen Saturation
Time Frame: Fifteen weeks
|
Change from baseline in Oxygen Saturation
|
Fifteen weeks
|
Arterial blood flow
Time Frame: Seven weeks
|
Change from baseline in Arterial blood flow in the radial and ulnar artery
|
Seven weeks
|
Arterial blood flow
Time Frame: Fifteen weeks
|
Change from baseline in Arterial blood flow in the radial and ulnar artery
|
Fifteen weeks
|
Upper limb disability
Time Frame: Seven Weeks
|
Change from baseline in the Disabilities of the Arm, Shoulder and Hand Questionnaire.
The score ranges from 0 (no disability) to 100 (most severe disability).
Higher scores indicate a greater level of disability and severity.
|
Seven Weeks
|
Upper limb disability
Time Frame: Fifteen Weeks
|
Change from baseline in the Disabilities of the Arm, Shoulder and Hand Questionnaire.
The score ranges from 0 (no disability) to 100 (most severe disability).
Higher scores indicate a greater level of disability and severity.
|
Fifteen Weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mª Encarnación ME Aguilar Ferrándiz, PhD, Universidad de Granada
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Ray-2016
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Raynaud Disease
-
University of Toledo Health Science CampusElectroCore INCTerminatedRaynaud Disease | Raynaud Phenomenon | Primary Raynaud Phenomenon | Raynaud SyndromeUnited States
-
University of MinnesotaWithdrawnRaynaud Disease | Raynaud Phenomenon | Raynaud SyndromeUnited States
-
University of Central FloridaTerminatedRaynaud PhenomenonUnited States
-
University of NottinghamCompleted
-
University Medical Center GroningenRecruiting
-
University Hospital, GrenobleUniversity Hospital, RouenRecruitingRaynaud PhenomenonFrance
-
Assistance Publique - Hôpitaux de ParisCompleted
-
University of CologneCompleted
-
Lawson Health Research InstituteDelivra, Inc.Withdrawn
-
Northwestern UniversityEli Lilly and CompanyCompleted
Clinical Trials on Electrotherapy with Galvanic Current
-
Ege UniversityCompletedPain | Edema | Radius Fractures
-
Tufts UniversityRecruitingAnxiety | Cognitive DeficitUnited States
-
University of RzeszowRecruitingCervical Spine SyndromePoland
-
Centre d'Investigation Clinique et Technologique...University of VersaillesTerminated
-
Schoen Clinic Bad AiblingGerman Center for Vertigo and Balance DisordersUnknownSpatial Neglect After Right Brain-damageGermany
-
Brooke Army Medical CenterUnknownAnger | Irritability | Combat Related SymptomsUnited States
-
Anhui Medical UniversityUnknownMajor Depressive Disorder | Transcranial Direct Current Stimulation | Event-Related PotentialsChina
-
Cairo UniversityCompleted
-
University of ArkansasRecruiting
-
Saglik Bilimleri UniversitesiMedical Park Hospital IstanbulCompletedChronic Pain | Neck PainTurkey